GSK2879552 2HCl

For research use only.

Catalog No.S7796

14 publications

GSK2879552 2HCl Chemical Structure

CAS No. 1902123-72-1

GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.

Selleck's GSK2879552 2HCl has been cited by 14 publications

1 Customer Review

  • Effects of LSD1 inhibitors in acute myeloid leukaemia cells. Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells. Means±SEM of each two (caspase 3/7 activity) or three (flow cytometric analyses) separate measurements are shown.

    Br J Haematol, 2017, doi: 10.1111/bjh.14983. GSK2879552 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Histamine Receptor Inhibitors

Biological Activity

Description GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.
LSD1 [1]
(Cell-free assay)
1.7 μM(Ki)
In vitro

In 165 cell lines, GSK2879552 inhibits the growth of 9/28 small cell lung carcinoma (SCLC) lines and 20/29 AML lines ranged from 40% to 100%. The subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
THP-1 M2\3S2Z2dmO2aX;uJIF{e2G7 NV[1SXdROCxiNzygOFctKGGwZDCzNFAxKG6P NXzDbFZGOSCmYYm= MoDoZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBETDFzYjDhcoQhS0R6NjDlfJBz\XO|aX;uJJdqfGhiYY\ldoFo\SCHQ{WwJJZidHWnczDv[kAzOyBtLz2gOEBvVQ>? MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3MUS4NFQoRjNyNUG0PFA1RC:jPh?=
MOLM-13 M4TE[XBzd2yrZnXyZZRqd25iYYPzZZk> MVS2JIRigXN? MWLkc5NmKHKnc4DvcpNqfmViZHXjdoVie2ViaX6gRpJlXSC|aXfuZYwtKEWFNUCgQUAyNjliKz:tJFAvQSCwTR?= NV\s[lczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C1NVQ5ODRpPkOwOVE1QDB2PD;hQi=>
MV4-11 MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M32wWVI1OCCqcoO= MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB{NECgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1zLkG2{txO NVHRcGNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C3NVMxOjNpPkOwO|E{ODJ|PD;hQi=>

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
H3 / H3K4me1 / H3K4me2 / LSD1 ; 

PubMed: 26175415     

Western analysis of global H3K4me1 and H3K4me2 from NCI-H526 cell lysates after 24 hr of treatment with GSK2879552. The recombinant histones with specific modifications were used as antibody controls. Histone H3 and tubulin were used as the loading controls.

Growth inhibition assay
Cell viability; 

PubMed: 30514804     

Dose response curves of MOLM-13 (left) and OCI-AML3 (right) cells treated with a titration of GSK2879552 ± 1, 10, 100, or 1000 nM ATRA for four days. Values were graphed relative to the appropriate ATRA alone concentration for each curve.

In vivo In SCLC xenograft bearing mice, GSK2879552 (1.5 mg/kg, p.o.) demonstrates tumor growth inhibition by 17%-83%. [1]


Kinase Assay:[1]
- Collapse

LSD1 enzyme assay:

LSD1 activity was measured using a horseradish peroxidase (HRP) coupled assay with amplex red as an electron donor. The formation of product over time is measured using fluorescence intensity, Ex 531 nm and Em 595 nm, in a PerkinElmer EnVision plate reader. Final assay conditions are: 5 nM LSD1, 2.5 μM H3K4me2 peptide, 50 mM HEPES pH 7, 1 U/ml of HRP, 1 mM CHAPS, 0.03% dBSA and 10 μM amplex red.
Cell Research:[1]
- Collapse
  • Cell lines: 165 human cancer cell lines
  • Concentrations: ~10 μM
  • Incubation Time: 6 d
  • Method: The optimal cell seeding is determined empirically for all cell lines by examining the growth of a wide range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 6 days. Cells are then plated at the optimal seeding density 24 h before treatment (in duplicate) with a 20-point twofold dilution series of GSK2879552 or 0.15% DMSO. Plates are incubated for 6 days at 37°C in 5% CO2. Cells are then lysed with CellTiter-Glo (CTG) (Promega) and chemiluminescent signal is detected with a TECAN Safire2 microplate reader. In addition, an untreated plate of cells is harvested at the time of compound addition (T0) to quantify the starting number of cells. CTG values obtained after the 6 day treatment are expressed as a percent of the T0 value and plotted against compound concentration. Data are fit with a four-parameter equation to generate a concentration response curve and the concentration of GSK126 required to inhibit 50% of growth (growth IC50) is determined.
    (Only for Reference)

Solubility (25°C)

In vitro Water 44 mg/mL (100.59 mM)
DMSO 29 mg/mL (66.3 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.4


CAS No. 1902123-72-1
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CCC1CNC2CC2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02929498 Terminated Drug: GSK2879552|Drug: Azacitidine Myelodysplastic Syndrome|Myelodysplastic Syndromes GlaxoSmithKline|Parexel July 31 2017 Phase 1|Phase 2
NCT02177812 Terminated Drug: GSK2879552|Drug: ATRA Leukaemia Myelocytic Acute GlaxoSmithKline August 27 2014 Phase 1
NCT02034123 Terminated Drug: GSK2879552 Carcinoma Small Cell GlaxoSmithKline February 4 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Histamine Receptor Signaling Pathway Map

Related Histamine Receptor Products

Tags: buy GSK2879552 2HCl | GSK2879552 2HCl supplier | purchase GSK2879552 2HCl | GSK2879552 2HCl cost | GSK2879552 2HCl manufacturer | order GSK2879552 2HCl | GSK2879552 2HCl distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID